FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015015957> ?p ?o ?g. }

• W2015015957 endingPage "480" @default.
• W2015015957 startingPage "472" @default.
• W2015015957 abstract "Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors.We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients.A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy." @default.
• W2015015957 created "2016-06-24" @default.
• W2015015957 creator A5014949775 @default.
• W2015015957 creator A5021376490 @default.
• W2015015957 creator A5022108188 @default.
• W2015015957 creator A5023742645 @default.
• W2015015957 creator A5024312323 @default.
• W2015015957 creator A5026593581 @default.
• W2015015957 creator A5037149615 @default.
• W2015015957 creator A5040359760 @default.
• W2015015957 creator A5045437866 @default.
• W2015015957 creator A5050651568 @default.
• W2015015957 creator A5060580923 @default.
• W2015015957 creator A5072185005 @default.
• W2015015957 creator A5072876748 @default.
• W2015015957 creator A5074808453 @default.
• W2015015957 creator A5077388635 @default.
• W2015015957 creator A5081961039 @default.
• W2015015957 creator A5082182576 @default.
• W2015015957 creator A5085336500 @default.
• W2015015957 creator A5087008342 @default.
• W2015015957 creator A5090618504 @default.
• W2015015957 creator A5091057405 @default.
• W2015015957 date "2002-08-15" @default.
• W2015015957 modified "2023-10-17" @default.
• W2015015957 title "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors" @default.
• W2015015957 cites W120419820 @default.
• W2015015957 cites W1991417422 @default.
• W2015015957 cites W1995634658 @default.
• W2015015957 cites W1995930366 @default.
• W2015015957 cites W1999614615 @default.
• W2015015957 cites W2000998080 @default.
• W2015015957 cites W2008920989 @default.
• W2015015957 cites W2016086822 @default.
• W2015015957 cites W2021929996 @default.
• W2015015957 cites W2023004333 @default.
• W2015015957 cites W2027839460 @default.
• W2015015957 cites W2079420659 @default.
• W2015015957 cites W2113844763 @default.
• W2015015957 cites W2134094496 @default.
• W2015015957 cites W2312804644 @default.
• W2015015957 cites W2314511842 @default.
• W2015015957 cites W2324850882 @default.
• W2015015957 cites W2328017321 @default.
• W2015015957 cites W2329648702 @default.
• W2015015957 doi "https://doi.org/10.1056/nejmoa020461" @default.
• W2015015957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12181401" @default.
• W2015015957 hasPublicationYear "2002" @default.
• W2015015957 type Work @default.
• W2015015957 sameAs 2015015957 @default.
• W2015015957 citedByCount "3903" @default.
• W2015015957 countsByYear W20150159572012 @default.
• W2015015957 countsByYear W20150159572013 @default.
• W2015015957 countsByYear W20150159572014 @default.
• W2015015957 countsByYear W20150159572015 @default.
• W2015015957 countsByYear W20150159572016 @default.
• W2015015957 countsByYear W20150159572017 @default.
• W2015015957 countsByYear W20150159572018 @default.
• W2015015957 countsByYear W20150159572019 @default.
• W2015015957 countsByYear W20150159572020 @default.
• W2015015957 countsByYear W20150159572021 @default.
• W2015015957 countsByYear W20150159572022 @default.
• W2015015957 countsByYear W20150159572023 @default.
• W2015015957 crossrefType "journal-article" @default.
• W2015015957 hasAuthorship W2015015957A5014949775 @default.
• W2015015957 hasAuthorship W2015015957A5021376490 @default.
• W2015015957 hasAuthorship W2015015957A5022108188 @default.
• W2015015957 hasAuthorship W2015015957A5023742645 @default.
• W2015015957 hasAuthorship W2015015957A5024312323 @default.
• W2015015957 hasAuthorship W2015015957A5026593581 @default.
• W2015015957 hasAuthorship W2015015957A5037149615 @default.
• W2015015957 hasAuthorship W2015015957A5040359760 @default.
• W2015015957 hasAuthorship W2015015957A5045437866 @default.
• W2015015957 hasAuthorship W2015015957A5050651568 @default.
• W2015015957 hasAuthorship W2015015957A5060580923 @default.
• W2015015957 hasAuthorship W2015015957A5072185005 @default.
• W2015015957 hasAuthorship W2015015957A5072876748 @default.
• W2015015957 hasAuthorship W2015015957A5074808453 @default.
• W2015015957 hasAuthorship W2015015957A5077388635 @default.
• W2015015957 hasAuthorship W2015015957A5081961039 @default.
• W2015015957 hasAuthorship W2015015957A5082182576 @default.
• W2015015957 hasAuthorship W2015015957A5085336500 @default.
• W2015015957 hasAuthorship W2015015957A5087008342 @default.
• W2015015957 hasAuthorship W2015015957A5090618504 @default.
• W2015015957 hasAuthorship W2015015957A5091057405 @default.
• W2015015957 hasBestOaLocation W20150159571 @default.
• W2015015957 hasConcept C121608353 @default.
• W2015015957 hasConcept C126322002 @default.
• W2015015957 hasConcept C143998085 @default.
• W2015015957 hasConcept C170493617 @default.
• W2015015957 hasConcept C197934379 @default.
• W2015015957 hasConcept C2777583451 @default.
• W2015015957 hasConcept C2778375690 @default.
• W2015015957 hasConcept C2778729363 @default.
• W2015015957 hasConcept C2778820342 @default.
• W2015015957 hasConcept C2779490328 @default.
• W2015015957 hasConcept C3019892230 @default.
• W2015015957 hasConcept C42362537 @default.

• next